Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Olema Pharmaceuticals Inc (NQ: OLMA )

9.930 +0.030 (+0.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Olema Pharmaceuticals Inc

< Previous 1 2 Next >
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) Near the Top of Equities by Percentage Gain on 2/1
Via Investor Brand Network
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 11/28
Via Investor Brand Network
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 11/13
Via Investor Brand Network
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Olema Oncology
Via GlobeNewswire
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 11/9
Via Investor Brand Network
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 11/8
Via Investor Brand Network
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 11/7
Via Investor Brand Network
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is a Stock Spotlight on 10/16
Via Investor Brand Network
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences in November
From Olema Oncology
Via GlobeNewswire
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
From Olema Oncology
Via GlobeNewswire
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
Mr. Garland brings significant industry expertise with a long track record of successful launches 
From Olema Oncology
Via GlobeNewswire
Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
From Olema Oncology
Via GlobeNewswire
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
Preclinical data to be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 
From Olema Oncology
Via GlobeNewswire
Olema Oncology Announces Expansion of Collaboration Agreement with Novartis
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.